Status:
COMPLETED
Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Primary Objective 1\. To develop a pharmacokinetic-pharmacodynamic (PD) model for optimisation of docetaxel dosing Secondary Objectives 1. To establish an exposure-toxicity (neutropenia) relationsh...
Detailed Description
Rationale Poor tolerance of standard docetaxel dosage regimens used as a single agent in Asians has been clearly demonstrated by our group in 2 separate studies. Neutropenia emerged as the most promi...
Eligibility Criteria
Inclusion
- Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which docetaxel is indicated.
- Patients must have measurable or evaluable disease.
- With the exception of alopecia, fatigue, nausea and asthenia, patients must have resolution of all acute toxic effects of any prior surgery' radiotherapy or chemotherapy to National Cancer Institute (NCI) Common Toxicity Criteria version 3.0 (see Appendix A) grade \< 1.
- Patients must have ECOG performance status \< 2 (Karnofsky \>60%, see Appendix B).
- Patients must have a life expectancy of greater than 3 months.
- Patients must have normal renal and marrow function as defined below:
- leukocytes ≥3,000/μl
- absolute neutrophil count ≥1,500/μl
- platelets ≥100,000/μl
- haemoglobin ≥7g/dL
- creatinine ≤1.5 X institutional upper limit of normal
- Patients with abnormal liver function tests (AST/ALT ≤ 10 x institutional upper limits of normal; SAP \< 5x ULN; total bilirubin ≤ 1.5x ULN) will be eligible for enrolment.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Females with childbearing potential must have a negative serum pregnancy test within 7days prior to study enrollment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Patients may not be receiving any other investigational agents.
- Patients who have rapidly progressive intracranial or spinal metastatic disease (including patients who require corticosteroid for CNS disease).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or other agents used in study.
- Patients who have prior medications known to be metabolized by or induce/inhibit CYP3A4 within 1 week (see appendix C).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women are excluded from this study because docetaxel is embryotoxic/fetotoxic with the potential for abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with docetaxel, breastfeeding should be discontinued if the mother is treated with docetaxel. These potential risks may also apply to other agents used in this study.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00703378
Start Date
May 1 2006
End Date
February 1 2012
Last Update
March 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore